Patent · US Active

CTLA-4 aptamer siRNA species

US10711272B2 · kind B2 · utility

3Cited by

1References

16Claims

0Family size

Assignee

City of Hope · US

Inventors

Hua Yu · Glendora, US
Andreas Herrmann · Stuttgart, DE
Marcin Tomasz Kortylewski · Rancho Cucamonga, US

Key dates

Filing date	Jan 21, 2015
Grant date	Jul 14, 2020
Priority date	—
Expiry date	Jan 21, 2035

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2320/32
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided herein are, inter alia, nucleic acid compounds useful for targeting CTLA-4-expressing cells and modulating cell activity of the CTLA-4-expressing cells. The compositions provided herein may be part of pharmaceutical compositions and may be used for treatment of cancer, inflammatory diseases, infectious diseases or metabolic diseases.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.